Skip to main content

Table 4 Distribution of DAS28-CRP scores used in analyses

From: Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement

Months BEFORE start of DMARD of interest

N

Mean DAS28-CRP (± SD)

0

46

4.1 ± 1.6

1

19

4.8 ± 1.5

2

18

4.7 ± 1.3

3

21

4.0 ± 1.6

4

28

3.6 ± 1.6

5

13

3.8 ± 1.8

6

11

3.8 ± 1.5

7

21

4.0 ± 1.9

8

21

4.1 ± 1.2

9

22

4.3 ± 1.3

10

15

4.2 ± 1.4

11

16

4.1 ± 1.4

12+

18

4.3 ± 1.9

Months AFTER start of DMARD of interest

N

Mean DAS28-CRP (± SD)

0

3

5.6 ± 0.8

1

21

4.2 ± 1.5

2

29

4.2 ± 1.5

3

25

3.8 ± 1.5

4

20

4.3 ± 1.3

5

16

3.6 ± 1.6

6

12

2.7 ± 1.0

7

14

3.4 ± 1.6

8

26

3.7 ± 1.3

9

25

3.8 ± 1.6

10

20

3.0 ± 1.2

11

19

4.0 ± 1.6

12+

39

3.1 ± 1.4

  1. DAS28-CRP disease activity score based on 28 joints - C-reactive protein, DMARD disease-modifying antirheumatic drug